Doxycycline hinders phenylalanine fibril assemblies revealing a potential novel therapeutic approach in phenylketonuria

Ada De Luigi, Alessandro Mariani, Massimiliano De Paola, Andrea Re Depaolini, Laura Colombo, Luca Russo, Valeria Rondelli, Paola Brocca, Lihi Adler-Abramovich, Ehud Gazit, Elena Del Favero, Laura Cantù, Mario Salmona

Research output: Contribution to journalArticlepeer-review


A new paradigm for the aetiopathology of phenylketonuria suggests the presence of amyloid-like assemblies in the brains of transgenic mouse models and patients with phenylketonuria, possibly shedding light on the selective cognitive deficit associated with this disease. Paralleling the amyloidogenic route that identifies different stages of peptide aggregation, corresponding to different levels of toxicity, we experimentally address for the first time, the physico-chemical properties of phenylalanine aggregates via Small Angle, Wide Angle X-ray Scattering and Atomic Force Microscopy. Results are consistent with the presence of well-structured, aligned fibres generated by milliMolar concentrations of phenylalanine. Moreover, the amyloid-modulating doxycycline agent affects the local structure of phenylalanine aggregates, preventing the formation of well-ordered crystalline structures. Phenylalanine assemblies prove toxic in vitro to immortalized cell lines and primary neuronal cells. Furthermore, these assemblies also cause dendritic sprouting alterations and synaptic protein impairment in neurons. Doxycycline counteracts these toxic effects, suggesting an approach for the development of future innovative non-dietary preventive therapies.

Original languageEnglish
Article number15902
JournalScientific Reports
Publication statusPublished - Oct 29 2015

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Doxycycline hinders phenylalanine fibril assemblies revealing a potential novel therapeutic approach in phenylketonuria'. Together they form a unique fingerprint.

Cite this